Treace outlines $206M-$210M 2026 revenue range while targeting $700M TAM expansion
Earnings Call Insights: Treace Medical Concepts (TMCI) Q3 2026
Management View
"We're encouraged by our third quarter performance, driven by double-digit case volume growth and continued market share gains" (Founder, Chairman & CEO John Treace).
"We're narrowing our full year
Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.